Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2003

View Archived Issues

Three series of antitumor agents prepared and tested at Synta

First-quarter development at Esperion

Roche patents retinoid receptor agonists for emphysema and other uses

Novel tyrosine kinase inhibitors under study at Merck & Co.

GSK researchers describe new beta2-adrenoceptor agonists for use in respiratory disorders

New GSK-3 inhibitor with utility in diabetes therapy

Aventis scientists identify novel protein kinase inhibitors

Novo Nordisk and Boehringer Ingelheim describe new histamine H3 receptor modulators

New antidiabetic agents in early development at Merck KGaA

Novel modulators of LPA receptors and their use in cancer, wound healing, etc.

New iGluR5 antagonists in Lilly development pipeline

Procyon completes acquisition of Pharmacor

EyeTech enters Xalatan commercialization agreement with Pfizer

Arrow's RSV compound enters preclinical testing

Initiation of phase I/II study of CG-7870 plus radiation in early-stage prostate cancer

Diatos licenses European rights for Super-Leu-Dox

ISIS-23722 selected for clinical development

Microscience develops oral anthrax vaccine

FDA approves Oxycyte clinical protocol

Positive results from second phase III trial of immediate-release indiplon

Phase II Oxytrex study completes enrollment

Ilomastat successful in treating exposure to mustard gas

FTY-720 protects rats against experimental autoimmune encephalomyelitis

Neurokinin NK1 receptor antagonism prevents cytokine-mediated liver injury

NIH licensing opportunity: method of promoting T-cell migration to tumor vasculature

sFRP and peptide motifs that interact with sFRP and methods of use available for licensing from NIH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...